JAMA Oncology—A New Member of The JAMA Network Family of Journals

Mary L. Disis, MD; Thomas J. Easley; Howard Bauchner, MD

Over the next 2 decades the number of patients worldwide newly diagnosed with cancer is expected to increase from 14 million to 22 million annually and the number of annual cancer deaths globally is predicted to increase from 8.2 million to 13 million.¹ The scientific advances in oncology over the past decade have included oncogene-targeting monoclonal antibodies such as trastuzumab and cetuximab, novel agents directed against specific tumor mutations exemplified by crizotinib inhibiting ALK in lung cancer, blocking of immune checkpoints in tumors resulting in clinically meaningful antitumor immunity, and the assessment of individual cancer genomes for both cancer prognosis and treatment planning. Cancer care has come to represent the promise of personalized medicine. Cost, quality, value, end-of-life care, and survivorship have emerged as important new areas of investigation. From bench to bedside to community, oncology is a specialty rich in research and numerous complex and controversial clinical issues.

JAMA and The JAMA Network are pleased to announce the addition of a new journal—JAMA Oncology—to our network of journals. The journal will debut in early 2015 with a weekly online release that will include publication of major research articles, influential opinion articles (including Viewpoints and Invited Commentaries), and reviews (including systematic reviews, narrative reviews, and a collection of shorter article types) that will be focused on providing clinicians information about the latest advances in oncology. A print edition will be published monthly. In addition to publishing important research studies, we hope to encourage debate and discussion about important clinical and policy issues in oncology. The goal of the journal is to advance the science of oncology and improve the clinical care of patients with cancer.

The vision for JAMA Oncology is that it will become an important and influential journal for scientists, clinicians, and trainees in the field of oncology worldwide. The original, innovative, and timely scientific and educational content will provide a deeper understanding of cancer pathogenesis and recent treatment advances for clinicians and scientists. JAMA Oncology will convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community.

JAMA Oncology is committed to serving the author community efficiently. The goal will be to complete an initial internal review of submitted papers within a few days and external peer review and revision in 4 to 6 weeks and to ensure publication within 60 days of acceptance. For important transformative articles, more rapid review and publication will be possible.

As of October 1, 2014, JAMA Oncology will be accepting manuscript submissions for consideration for publication. The focus of the journal will be on medical, radiation, and surgical oncology and subspecialties. JAMA Oncology will emphasize manuscripts providing information that will be immediately clinically relevant. Definitive clinical trials, new diagnostic and prognostic tests ready for application, meta-analysis, observational studies, and health policy are a few of the areas of interest. Please visit http://oncology.jamanetwork.com to learn more about the journal, for information about submitting manuscripts, and to view the announcement Video.

We look forward to receiving manuscripts from authors and serving the information needs of clinicians, scientists, and other readers as we pursue the goal of advancing the science of oncology and improving the art of caring for patients with cancer.

ARTICLE INFORMATION

Author Affiliations: Center for Translational Medicine in Women’s Health and Institute of Translational Health Sciences, University of Washington, Seattle (Disis); Senior Vice President and Publisher, Periodical Publications, The JAMA Network (Easley); Editor in Chief, JAMA and The JAMA Network (Bauchner).

Corresponding Author: Howard Bauchner, MD, JAMA, 330 N Wabash Ave, Chicago, IL 60611 (howard.bauchner@jamanetwork.org).

Published Online: September 26, 2014. doi:10.1001/jama.2014.13944.

REFERENCE